Market Cap (In SEK)
129.52 Million
Revenue (In SEK)
49.87 Million
Net Income (In SEK)
-22.09 Million
Avg. Volume
33.33 Thousand
- Currency
- SEK
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 5.46-9.8
- PE
- -6.75
- EPS
- -0.65
- Beta Value
- 0.447
- ISIN
- SE0010219626
- CUSIP
- -
- CIK
- -
- Shares
- 29504000.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Mr. Peter Nahlstedt
- Employee Count
- -
- Website
- https://senzagen.com
- Ipo Date
- 2017-09-21
- Details
- SenzaGen AB develops, performs, and sells non-animal tests for assessing a substance's allergenicity. The company offers genomic allergen rapid detection (GARD)skin, an in vitro test to identify potential chemical skin sensitizers; GARDpotency, an in vitro add-on test to GARDskin for potency classification; GARDskin Dose-response, an in vitro test for quantitative skin sensitizing potency assessment of chemicals; and GARDair, an in vitro test for identifying chemical respiratory sensitizers, as well as GARDskin medical device, an in vitro skin sensitization testing for medical devices and solid materials. It also provides irritation and corrosion testing services. The company offers services through license partners and distributors. It has a collaboration agreement with the Research Institute for Fragrance Materials to develop tests for photosensitization. The company was incorporated in 2010 and is headquartered in Lund, Sweden.
More Stocks
-
7369Meiho Holdings,Inc.
7369
-
VACNYVAT Group AG
VACNY
-
BRZEBraze, Inc.
BRZE
-
TDW-WTTidewater Inc.
TDW-WT
-
BOCN
-
600015Hua Xia Bank Co., Limited
600015
-
2175SMS Co., Ltd.
2175
-
ALARKAlarko Holding A.S.
ALARK